Info

MaxCyte was founded in 1999 to commercialize flow electroporation technology exclusively from the CBR Institute for Biomedical Research. The technology was intended for clinical use, and the application that had been proposed when the technology was first acquired involved loading 1 liter of autologous red blood cell suspension with an alternative hemoglobin oxygen modulator to yield a therapy for ischemic disorders. MaxCyte set out to pursue the red blood cell application and to investigate use of the technology for loading a wide range of biologically active molecules into many types of cells. The system has been significantly refined and many applications explored, but the original plan, to develop a system primarily intended for clinical use in a near patient setting, has been the guiding principle.